​Recent studies have demonstrated the efficacy of semaglutide, a GLP-1 receptor agonist, in promoting significant weight loss among individuals with overweight or obesity. Here are some notable findings:​

1. STEP 5 Trial (2022): Over a 104-week period, participants receiving once-weekly subcutaneous semaglutide 2.4 mg experienced an average weight reduction of 15.2%, compared to 2.6% in the placebo group.

2. STEP UP Trial (2025): This 72-week study investigated a higher dose of semaglutide (7.2 mg) and found an average weight loss of 20.7% among participants, with 33.2% achieving a reduction of 25% or more.

3. Real-World Study (2024): A retrospective analysis indicated that semaglutide is effective for weight loss even at lower than approved maintenance doses, maintaining a favorable safety profile.

4. Comparative Study with Tirzepatide (2024): Research comparing semaglutide to tirzepatide, another medication, revealed that while both drugs led to significant weight loss, the benefit was greater with tirzepatide. 

These studies underscore semaglutide’s potential as a substantial treatment option for weight management in individuals with obesity or overweight conditions.